We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




World’s First AI Model for Thyroid Cancer Diagnosis Achieves Over 90% Accuracy

By LabMedica International staff writers
Posted on 25 Apr 2025

Thyroid cancer is one of the most common cancers worldwide, and its precise management typically relies on two primary systems: (1) the 8th edition of the American Joint Committee on Cancer (AJCC) or Tumor-Node-Metastasis (TNM) cancer staging system, which helps determine the stage of cancer, and (2) the American Thyroid Association (ATA) risk classification system, which is used to categorize cancer risk. More...

These systems are vital for predicting patient survival and guiding treatment decisions. However, manually integrating the complex clinical data into these systems can be time-consuming and inefficient. Now, researchers have introduced the world’s first artificial intelligence (AI) model capable of classifying both the stage and risk category of thyroid cancer with remarkable accuracy, exceeding 90%. This innovative AI model, featured in the journal npj Digital Medicine, is set to significantly reduce pre-consultation preparation time for frontline clinicians by approximately 50%.

An interdisciplinary research team from the LKS Faculty of Medicine at the University of Hong Kong (HKUMed, Hong Kong) developed an AI assistant that employs large language models (LLMs) such as ChatGPT and DeepSeek. These models are designed to understand and process human language, helping to analyze clinical documents and improve the accuracy and efficiency of thyroid cancer staging and risk classification. The model utilizes four offline, open-source LLMs—Mistral (Mistral AI), Llama (Meta), Gemma (Google), and Qwen (Alibaba)—to interpret free-text clinical documents. The AI model was trained using an open-access data set from the United States that included pathology reports from 50 thyroid cancer patients from The Cancer Genome Atlas Program (TCGA), with validation done using pathology reports from 289 TCGA patients and 35 pseudo cases created by endocrine surgeons.

By combining the outputs from all four LLMs, the research team was able to enhance the overall performance of the AI model, achieving an accuracy rate ranging from 88.5% to 100% in ATA risk classification and 92.9% to 98.1% in AJCC cancer staging. In addition to its high accuracy in extracting and analyzing complex information from pathology reports, operation records, and clinical notes, the AI model also drastically reduces doctors’ preparation time by nearly half compared to manual interpretation. A significant advantage of this model is its ability to operate offline, allowing it to be deployed locally without the need to share or upload sensitive patient data, thereby ensuring maximum patient privacy. The AI model’s versatility means it can be easily integrated into a variety of healthcare settings, both public and private, as well as in international healthcare and research institutions.

“In line with government’s strong advocacy of AI adoption in healthcare, as exemplified by the recent launch of LLM-based medical report writing system in the Hospital Authority, our next step is to evaluate the performance of this AI assistant with a large amount of real-world patient data,” said Dr. Carlos Wong, Honorary Associate Professor in the Department of Family Medicine and Primary Care, School of Clinical Medicine, HKUMed. “Once validated, the AI model can be readily deployed in real clinical settings and hospitals to help clinicians improve operational and treatment efficiency.”

Related Links:
HKUMed


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain

Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more

Molecular Diagnostics

view channel
Image Credit: 123RF

Genetic Testing Program Helps Uncover Inherited Risk in Pediatric Cancer

Inherited cancer risk can affect children, adolescents and young adults, but it may not always be apparent from tumor type or family history alone. Some cancer syndromes require specialized expertise and... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.